Welcome to our dedicated page for Zomedica SEC filings (Ticker: ZOM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want to know if Zomedica’s TRUFORMA sales are gaining traction or how much cash the company burned last quarter? Start here. Stock Titan gathers every Zomedica SEC filing the moment it hits EDGAR and layers in AI-powered summaries so you can understand complex veterinary-tech disclosures without wading through 200 pages.
Use this page to quickly answer questions you already search for, including “Zomedica quarterly earnings report 10-Q filing”, “Zomedica insider trading Form 4 transactions”, or “how to read Zomedica’s annual report 10-K simplified”. Our platform links each form type to what matters for this company:
- 10-K and 10-Q drill into R&D spend, cash runway, and early sales of point-of-care devices—AI points out revenue trends in seconds.
- 8-K material events explained so you see regulatory clearances or distribution deals the day they’re announced.
- Form 4 insider transactions in real time, letting you spot executive stock transactions before the market absorbs them.
- Proxy statement executive compensation details, including equity awards tied to veterinary product milestones.
Every document is refreshed automatically, and our expert analysis converts legal jargon into plain English. Whether you’re monitoring “Zomedica Form 4 insider transactions real-time”, seeking “Zomedica earnings report filing analysis”, or simply “understanding Zomedica SEC documents with AI”, this page streamlines your research so you can make informed decisions faster.
Kevin Klass, Senior Vice President, Sales at Zomedica Corp., reported purchases of 60,723 shares on 08/11/2025 at $0.04, and 250,000 and 745,341 shares on 08/12/2025 at $0.04. Following these reported transactions, his beneficial ownership is shown sequentially as 4,260,753, 4,510,753 and 5,256,094 shares.
Zomedica Corp. reporting person Kevin Klass, Sr. Vice President of Sales, reported purchases on 08/11/2025 totaling 500,000 common shares in two transactions: 250,000 shares at $0.038 and 250,000 shares at $0.04. The filings show direct beneficial ownership rising to 4,200,030 shares. The Form 4 is signed on 08/12/2025. No derivative transactions are reported.
Kevin Klass, Senior Vice President of Sales at Zomedica Corp., reported acquiring 500,000 shares of common stock on 08/08/2025 at $0.04 per share under transaction code P (pursuant to a written plan). Following this transaction his reported beneficial ownership is 3,700,030 shares, held directly.
FAQ
What is the current stock price of Zomedica (ZOM)?
What is the market cap of Zomedica (ZOM)?
